Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads skin lesions to predict cancer aggressiveness

NCT ID NCT07677124

Knowledge-focused Sponsor: Istanbul Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests whether an artificial intelligence (AI) model can accurately classify basal cell carcinoma (a common skin cancer) as low-risk or high-risk using dermoscopic images. Researchers will also see if the AI can predict specific subtypes of the cancer. The model's performance will be compared to diagnoses made by dermatologists. The study uses existing data from patients with confirmed basal cell carcinoma.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this AI model could help doctors quickly identify high-risk skin cancers from images, potentially speeding up treatment decisions.
What could go wrong
This is a retrospective study using existing images, so the AI may not perform as well in real-world settings. It is not a treatment and does not directly benefit participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of patients with histopathologically confirmed basal cell carcinoma who have dermoscopic images of sufficient quality for artificial intelligence analysis and documented histopathological subtype information. Archived clinical and dermoscopic images collected at Istanbul Training and Research Hospital will be retrospectively analyzed.

Ages

0 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with histopathologically confirmed basal cell carcinoma. * Cases with a specified histopathological subtype. * Availability of dermoscopic images with sufficient image quality and resolution for artificial intelligence analysis. Exclusion Criteria: * Cases without histopathological confirmation of basal cell carcinoma. * Cases with unspecified histopathological subtype. * Images with insufficient quality or resolution for artificial intelligence analysis. * Cases without available dermoscopic images.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Basal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

basal cell carcinoma skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Basal cell carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istanbul Training and Research Hospital

    RECRUITING

    Istanbul, Istanbul, 34000, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.